JP2005509624A5 - - Google Patents

Download PDF

Info

Publication number
JP2005509624A5
JP2005509624A5 JP2003535800A JP2003535800A JP2005509624A5 JP 2005509624 A5 JP2005509624 A5 JP 2005509624A5 JP 2003535800 A JP2003535800 A JP 2003535800A JP 2003535800 A JP2003535800 A JP 2003535800A JP 2005509624 A5 JP2005509624 A5 JP 2005509624A5
Authority
JP
Japan
Prior art keywords
group
alkyl
substituted
atom
imino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003535800A
Other languages
English (en)
Japanese (ja)
Other versions
JP4460292B2 (ja
JP2005509624A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/011453 external-priority patent/WO2003032997A1/de
Publication of JP2005509624A publication Critical patent/JP2005509624A/ja
Publication of JP2005509624A5 publication Critical patent/JP2005509624A5/ja
Application granted granted Critical
Publication of JP4460292B2 publication Critical patent/JP4460292B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003535800A 2001-10-17 2002-10-14 ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 Expired - Lifetime JP4460292B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33014501P 2001-10-17 2001-10-17
PCT/EP2002/011453 WO2003032997A1 (de) 2001-10-17 2002-10-14 Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung

Publications (3)

Publication Number Publication Date
JP2005509624A JP2005509624A (ja) 2005-04-14
JP2005509624A5 true JP2005509624A5 (https=) 2006-01-05
JP4460292B2 JP4460292B2 (ja) 2010-05-12

Family

ID=23288491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003535800A Expired - Lifetime JP4460292B2 (ja) 2001-10-17 2002-10-14 ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法

Country Status (12)

Country Link
US (3) US7173028B2 (https=)
EP (3) EP2332924A1 (https=)
JP (1) JP4460292B2 (https=)
AT (1) ATE407678T1 (https=)
CA (1) CA2463989C (https=)
CY (1) CY1110442T1 (https=)
DE (1) DE50212771D1 (https=)
DK (1) DK1438053T3 (https=)
ES (1) ES2314106T3 (https=)
PT (1) PT1438053E (https=)
UY (1) UY27487A1 (https=)
WO (1) WO2003032997A1 (https=)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0209774A (pt) 2001-05-29 2004-06-01 Schering Ag Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
AU2002316421B2 (en) 2001-06-26 2008-05-15 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-ALPHA expression
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
IL161663A0 (en) * 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3beta INHIBITORS
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2478156C (en) 2002-03-26 2011-02-15 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003095448A1 (en) * 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
DK1519939T5 (da) * 2002-07-05 2011-01-24 Targacept Inc N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
WO2004019935A1 (en) * 2002-08-29 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Chk−、Pdk−およびAkt−阻害性ピリミジン、それらの製造および薬剤としての使用
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2529611C (en) * 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20040242613A1 (en) * 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
ES2325440T3 (es) * 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
AU2004256124B2 (en) * 2003-07-02 2011-04-28 Corus Pharma, Inc. Aztreonam L-lysine and methods for the preparation thereof
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2005023780A1 (en) * 2003-09-05 2005-03-17 Pfizer Products Inc. Selective synthesis of cf3-substituted pyrimidines
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
CA2541059C (en) * 2003-10-03 2013-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescent probes for use in protein kinase inhibitor binding assay
CA2547080A1 (en) * 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
EP2543376A1 (en) * 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
MXPA06011658A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP2007537230A (ja) * 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の処置用のピリミジン誘導体
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
JP2008505910A (ja) * 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Pkc−シータのインヒビターとして有用なピリミジン誘導体
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
CA2592514A1 (en) 2004-12-27 2006-07-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7659280B2 (en) 2006-02-17 2010-02-09 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
RU2008152195A (ru) * 2006-06-15 2010-07-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа
RU2008152193A (ru) * 2006-06-15 2010-07-20 Бёрингер Ингельхайм Интернациональ Гмбх (De) 2-амино-4-аминоалкиленаминопиримидины
CA2654670A1 (en) * 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
AU2007329548A1 (en) 2006-12-06 2008-06-12 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2008077885A2 (en) 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
CA2676715A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
US8252803B2 (en) * 2007-02-12 2012-08-28 Merck Sharp & Dohme Corp. Piperidine derivatives
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
US8461147B2 (en) * 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
CA2708262A1 (en) * 2007-12-07 2009-06-18 Elan Pharmaceuticals, Inc. Methods and compositions for treating liquid tumors
US20100056524A1 (en) * 2008-04-02 2010-03-04 Mciver Edward Giles Compound
EP2300472B1 (en) 2008-06-06 2012-01-18 Boehringer Ingelheim International GmbH Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP5644499B2 (ja) * 2008-09-01 2014-12-24 アステラス製薬株式会社 2,4−ジアミノピリミジン化合物
EA201100436A1 (ru) * 2008-09-03 2011-10-31 Байер Кропсайенс Аг Гетероциклически замещенные анилинопиримидины в качестве фунгицидов
KR20110049905A (ko) * 2008-09-03 2011-05-12 바이엘 크롭사이언스 아게 4-알킬-치환된 디아미노피리미딘
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179993A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) * 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
JP5599815B2 (ja) * 2008-12-19 2014-10-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
JP5815411B2 (ja) 2008-12-30 2015-11-17 ライジェル ファーマシューティカルズ, インコーポレイテッド ピリミジンジアミンキナーゼ阻害剤
CN102317265B (zh) * 2009-01-14 2015-03-25 里格尔药品股份有限公司 用于治疗炎性疾病的2,4-嘧啶二胺化合物
JP5781943B2 (ja) * 2009-01-21 2015-09-24 ライジェル ファーマシューティカルズ, インコーポレイテッド 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なn2−(3−ピリジルまたはフェニル)−n4−(4−ピペリジル)−2,4−ピリミジンジアミン誘導体
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sglt2阻害剤、dpp−iv阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
CN102421435A (zh) * 2009-04-28 2012-04-18 贝林格尔.英格海姆国际有限公司 使用PKC-θ抑制剂的免疫性疾病的离体治疗
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
CN106420756A (zh) * 2009-07-28 2017-02-22 里格尔药品股份有限公司 抑制jak途径的组合物和方法
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
EP2507227B1 (en) * 2009-12-01 2014-10-08 Rigel Pharmaceuticals, Inc. Tetrazolones as protein kinase c inhibitors and uses thereof
WO2011103196A1 (en) 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
ES2577829T3 (es) * 2010-06-04 2016-07-19 F. Hoffmann-La Roche Ag Derivados de aminopirimidina como moduladores de la LRRK2
DE102010034699A1 (de) * 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
NO2638031T3 (https=) 2010-11-10 2018-03-10
JP5959537B2 (ja) 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
US20130324532A1 (en) * 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
US9174946B2 (en) * 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
MX348920B (es) * 2011-11-29 2017-07-04 Genentech Inc Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
US9145402B2 (en) * 2011-11-29 2015-09-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN104736533B (zh) 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
HK1209104A1 (en) * 2012-08-17 2016-03-24 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN104903312B (zh) * 2013-10-07 2019-01-29 卡德门企业有限公司 Rho激酶抑制剂
KR101744033B1 (ko) * 2013-10-16 2017-06-07 후지필름 가부시키가이샤 함질소 복소환 화합물의 염 또는 그 결정, 의약 조성물 및 flt3 저해제
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
WO2015148867A1 (en) * 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN110229142A (zh) * 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
EP3195866B1 (en) 2014-08-22 2020-11-18 FUJIFILM Corporation Pharmaceutical composition for treating flt3 mutation-positive cancer, mutant flt3 inhibitor and uses thereof
WO2016205304A1 (en) * 2015-06-16 2016-12-22 Signal Pharmaceuticals, Llc Methods of treatment using substituted diaminopyrimidyl compounds
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
DE102017112612A1 (de) * 2016-06-10 2017-12-14 Hitachi High-Tech Science Corporation Flüssigkeitschromatograph und Verfahren zum Korrigieren von Schwankungen eines Detektorausgabewerts des Flüssigkeitschromatographen
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
KR101876514B1 (ko) * 2016-11-08 2018-07-10 한국화학연구원 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물
CA3048340A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
CN111417634A (zh) * 2017-10-04 2020-07-14 细胞基因公司 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法
MA55909A (fr) * 2019-05-05 2022-03-16 Qilu Regor Therapeutics Inc Inhibiteurs de cdk
US11518758B2 (en) 2019-05-10 2022-12-06 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PE20220597A1 (es) * 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PE20221083A1 (es) * 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
CN111187220B (zh) * 2020-01-19 2022-08-02 郑州大学 含席夫碱结构单元的三氟甲基嘧啶类衍生物及其制备方法和用途
CN111646978B (zh) * 2020-06-11 2021-12-21 浙江大学 N2-取代烷氧芳环-2-氨基嘧啶类衍生物及应用
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
US20240059678A1 (en) * 2021-01-18 2024-02-22 Hinova Pharmaceuticals Inc. Synthesis Method for Aminopyrimidine FAK Inhibitor Compound
US20240208934A1 (en) * 2021-04-07 2024-06-27 Lifearc Ulk1/2 inhibitors and their use thereof
WO2023122723A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Panels and methods for diagnosing and treating lung cancer
WO2024099225A1 (zh) * 2022-11-08 2024-05-16 微境生物医药科技(上海)有限公司 Ulk抑制剂
WO2024243485A1 (en) * 2023-05-25 2024-11-28 Odyssey Therapeutics, Inc. Cdk2 inhibitors and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2055900A (en) * 1935-03-11 1936-09-29 Daisy Mfg Co Toy gun
US2152960A (en) 1935-05-28 1939-04-04 Soc Of Chemical Ind Process for the manufacture of cyclohexanols
US2723975A (en) * 1952-04-03 1955-11-15 Nepera Chemical Co Inc 2, 4-di-piperidino-5-benzylpyrimidine
DE1249282B (https=) 1960-11-01
FR2358148A1 (fr) 1976-07-12 1978-02-10 Dick Pr Derives de 2,4-diaminopyrimidines et leur mise en solution en association avec des sulfamides
DE2709634A1 (de) * 1977-03-05 1978-09-07 Basf Ag Benzylpyrimidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE2730467A1 (de) * 1977-07-06 1979-01-18 Basf Ag Benzylpyrimidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE2756370A1 (de) * 1977-12-17 1979-06-21 Noell Gmbh Kombinierter greifer in einem kernreaktor
US4255568A (en) * 1979-04-18 1981-03-10 American Home Products Corporation 2H-Pyrimido[4,5-d][1,3]oxazine-2,4(1H)-dione derivatives
US4301281A (en) * 1979-04-18 1981-11-17 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]-pyrimidine-6-carboxylic acid amides
US4215216A (en) * 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
US4245094A (en) * 1980-01-28 1981-01-13 American Home Products Corporation 5-Amino-2,8-dialkyl-7,8-dihydro-7-oxo-pyrido-[2,3-d]pyrimidine-6 carboxylic acid derivatives
FR2502152A1 (fr) * 1981-03-20 1982-09-24 Panmedica Laboratoires Nouveaux derives solubles n2 substitues de la diamino-2,4-benzyl-5-pyrimidines, leur procede de preparation et medicaments les contenant
JPS6253973A (ja) 1985-09-02 1987-03-09 Mitsui Toatsu Chem Inc ハロゲノチオシアノピリミジン誘導体、その製造法および農園芸用殺菌剤
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
JPH03127790A (ja) 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
US5491234A (en) * 1992-03-30 1996-02-13 Pfizer Inc. Pyrimidine derivatives for enhancing antitumor activity
GB9212673D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
EA200000840A1 (ru) * 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
EA002973B1 (ru) 1998-03-27 2002-12-26 Янссен Фармацевтика Н.В. Производные пиримидина в качестве ингибиторов репликации вируса иммунодефицита человека
KR100643419B1 (ko) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Hiv를 억제하는 피리미딘 유도체
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
DE19851421A1 (de) * 1998-11-07 2000-05-11 Boehringer Ingelheim Pharma Neue Pyrimidine, deren Herstellung und Verwendung
SK287270B6 (sk) 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
WO2001000213A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
US7169778B2 (en) 1999-09-15 2007-01-30 Warner-Lambert Company Pteridinones as kinase inhibitors
CN1374953A (zh) * 1999-09-16 2002-10-16 田边制药株式会社 含氮的6-员芳香环化合物
TR200200763T2 (tr) 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
WO2001027105A1 (en) 1999-10-12 2001-04-19 Takeda Chemical Industries, Ltd. Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
EP1227741B1 (en) 1999-11-09 2005-09-07 Jozsef Mandzsu, Sr. Method and apparatus for producing the male component of a separable fastener, the product produced in this manner and the system containing this product
JP2003523358A (ja) 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 神経変性疾患の治療のためのピリドピリミジノン誘導体
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
US20080027037A1 (en) * 2000-04-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Cyclic compounds
CN1657523A (zh) * 2000-04-28 2005-08-24 田边制药株式会社 环状化合物
AU782948B2 (en) * 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
BR0116452A (pt) * 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
CZ20032233A3 (cs) 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
DE10127581A1 (de) 2001-05-29 2003-01-02 Schering Ag CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
BR0209774A (pt) * 2001-05-29 2004-06-01 Schering Ag Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
DE10212098A1 (de) 2002-03-11 2003-10-23 Schering Ag CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
JP3918048B2 (ja) 2001-07-03 2007-05-23 独立行政法人産業技術総合研究所 低級アルケンの製造方法
WO2003040141A1 (en) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003032994A2 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
ATE407678T1 (de) 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003082855A1 (en) 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
US20040242613A1 (en) 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta

Similar Documents

Publication Publication Date Title
JP2005509624A5 (https=)
CA2463989A1 (en) Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
US6649609B2 (en) Benzimidazole derivatives and pharmaceutical compositions comprising these compounds
KR101985050B1 (ko) 피라진카르복사미드 화합물
JP4796567B2 (ja) 選択されたcgrpアンタゴニスト、その製造方法及びその薬物としての使用
AU2013271733B2 (en) Compounds and compositions for modulating EGFR activity
DE60204722T2 (de) Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten
ES2324710T3 (es) Indolinonas sustituidas con heterociclos y su uso como inhibidores de receptores de tirosina quinasa.
ES2283754T3 (es) Piperidinas sustituidas con benzodiazepina para uso en el tratamiento de enfermedades cardiovasculares.
JP2006501273A5 (https=)
MXPA02002799A (es) Indolinas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos.
WO2019118799A1 (en) Substituted indole ether compounds
JP2011515462A5 (https=)
JP2007530617A6 (ja) 選択されたcgrpアンタゴニスト、その製造方法及びその薬物としての使用
ZA200502248B (en) Selected CGRP antagonists, method for production and use thereof as medicament
JP2007533689A (ja) 選択されたcgrpアンタゴニスト、その製造方法及びその薬物としての使用
HU211737A9 (en) Piperazine derivatives
JPH0873439A (ja) 1−ベンジル−1,3−ジヒドロ−2h−ベンズイミダゾール−2−オン誘導体、これらの調製およびこれらを含有する薬学的組成物
EP1163242A2 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US8436008B2 (en) Substituted heterocyclic compounds
WO2008033513A1 (en) ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS
RU2010120536A (ru) Производные пиридина и пиразина, полезные для лечения клеточных проферативных расстройств
ES2354162T3 (es) Derivados de pirazol como modulares de proteína quinasas.
HK1196127A (en) Compounds and compositions for modulating egfr activity
HK1196127B (en) Compounds and compositions for modulating egfr activity